Lian, Xizhen
Chatterjee, Sumanta
Sun, Yehui http://orcid.org/0000-0003-0215-6095
Dilliard, Sean A.
Moore, Stephen
Xiao, Yufen http://orcid.org/0000-0002-5604-7479
Bian, Xiaoyan http://orcid.org/0000-0002-6263-5269
Yamada, Kohki
Sung, Yun-Chieh
Levine, Rachel M. http://orcid.org/0000-0002-3684-2950
Mayberry, Kalin
John, Samuel http://orcid.org/0000-0002-4167-2466
Liu, Xiaoye http://orcid.org/0000-0001-5031-0822
Smith, Caroline
Johnson, Lindsay T. http://orcid.org/0000-0002-4563-5486
Wang, Xu http://orcid.org/0000-0002-8925-5645
Zhang, Cheng Cheng
Liu, David R.
Newby, Gregory A.
Weiss, Mitchell J.
Yen, Jonathan S.
Siegwart, Daniel J. http://orcid.org/0000-0003-3823-1931
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (5R01EB025192-06)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA269787-01, P30CA142543, 1R01 CA248736)
Welch Foundation (I-2123-20220031)
Cystic Fibrosis Foundation (SIEGWA18XX0)
Leukemia and Lymphoma Society (6629-21)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL156647)
Article History
Received: 22 July 2023
Accepted: 15 April 2024
First Online: 23 May 2024
Competing interests
: UT Southwestern has filed patent applications on the technologies described in this manuscript with X. Lian and D.J.S. listed as inventors. D.J.S. discloses the following competing interests: ReCode Therapeutics, Signify Bio, Tome Biosciences, Jumble Therapeutics and Pfizer Inc. D.R.L. is a consultant and equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver gene-editing or epigenome-modulating agents. M.J.W. is a consultant for GlaxoSmithKline, Cellarity, Novartis and Dyne Therapeutics. J.S.Y. is an equity owner of Beam Therapeutics. The remaining authors declare no competing interests.